Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2017-07-03 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
独立董事关于公司全资子公司出资1200万元投资北京原创客股权投资基金管理中心（有限合伙）的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Beijing SL Pharmaceutical Co., Ltd. regarding an investment decision by the company's wholly-owned subsidiary to invest 12 million yuan in an equity investment fund management center. The document references compliance with relevant laws and company regulations and expresses agreement with the board's resolution. It is a formal statement of opinion on a specific corporate action rather than a full financial report, audit, or earnings release. It does not contain financial statements or detailed financial data. The document is short (667 characters) and serves as a formal independent director opinion on a corporate investment decision, which aligns with Board/Management Information filings that announce or disclose board decisions or management opinions on company matters.
2017-07-03 Chinese
第六届董事会第十次临时会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a board resolution announcement from Beijing SL Pharmaceutical Co., Ltd. regarding an investment decision made by the company's wholly-owned subsidiary. It details the approval of an investment of 12 million RMB into an equity investment fund. The document includes information about the board meeting, voting, and compliance with company laws and regulations. There is no financial data, earnings information, or detailed report content. It is an announcement of a board decision related to capital investment, which fits best under Capital/Financing Update (CAP). The document length is short and it is not a report publication or certification. Therefore, the classification is CAP with high confidence.
2017-07-03 Chinese
2016年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the implementation of the 2016 annual dividend distribution plan by Beijing SL Pharmaceutical Co., Ltd. It details the dividend amount, payment dates, shareholder eligibility, tax treatment, and related procedural information. The document references the approval of the dividend plan at the 2016 Annual General Meeting and provides specifics on the dividend payment schedule and method. The document length is 2302 characters, which is relatively short and primarily serves as a formal announcement of the dividend distribution rather than the dividend report itself. Therefore, it fits the category of a Notice of Dividend Amount (DIV) rather than an Annual Report or other financial report type.
2017-06-27 Chinese
2016年度股东大会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2016 Annual General Meeting (AGM) of Beijing Shuanglu Pharmaceutical Co., Ltd. It details the procedures of convening and holding the AGM, the qualifications of attendees, the agenda items discussed, and the voting results. The document is not the AGM materials or presentations themselves but a legal opinion on the AGM's compliance and validity. It is not an announcement of voting results but a legal opinion letter. Given the content and nature, this fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it includes detailed voting results and legal validation of the AGM proceedings. The document length is 4366 characters, which is relatively short but contains substantive voting results and legal opinions, not just a brief announcement or a report publication notice. Therefore, the classification is DVA with high confidence.
2017-05-24 Chinese
2016年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2016 Annual General Meeting (AGM) of Beijing SL Pharmaceutical Co., Ltd. It includes information about the meeting date, attendance, voting results on various proposals including the 2016 annual report, financial statements, profit distribution plan, appointment of auditors, and other corporate matters. The document is not the annual report itself but the official announcement of the voting results and resolutions from the AGM. The length is 4217 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2017-05-24 Chinese
内部控制规则落实自查表
Regulatory Filings Classification · 95% confidence The document is titled as an "内部控制规则落实自查表" which translates to "Internal Control Rules Implementation Self-Inspection Form." It contains detailed internal control checklists related to internal audit operations, information disclosure controls, insider trading controls, fundraising controls, related party transactions, external guarantees, major investments, and other important matters. The document is a self-assessment or internal control checklist rather than a financial report or announcement. It does not contain financial statements, earnings data, or regulatory certifications. It is not an announcement of a report but a detailed internal control compliance document. This type of document fits best under Regulatory Filings (RNS) as it is a compliance/internal control disclosure that does not fit other specific categories like Annual Report, Audit Report, or Management Reports.
2017-04-27 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.